Multiple law-firm notices report that a securities-fraud class action has been filed against ADMA Biologics, Inc. (NASDAQ: ADMA) and certain of its officers. The complaints allege that investors are harmed in connection with ADMA’s stock dropping by about 29% following claims described as “channel stuffing” by Culper Research, which the filings characterize as potentially violating federal securities laws.
The notices consistently describe the class as covering purchasers or acquirers of ADMA securities between August 9, 2024 and March 25, 2026, inclusive. Several outlets highlight that affected investors may be able to seek appointment as lead plaintiff, which would allow them to play a prominent role in the litigation. One notice specifically emphasizes an August 10, 2026 deadline for submitting lead-plaintiff applications, while other notices remind investors to consider whether to participate and to watch for relevant court dates.
